An Acadia Pharmaceuticals Inc. shareholder slapped the biopharmaceutical company with a putative securities fraud class action in California federal court Thursday, claiming the company inflated its stock price by hiding safety risks and downplaying reports of deaths connected to its treatment for hallucinations and delusions.
The active ingredient in Monsanto's weed killers caused a retired groundskeeper's non-Hodgkin lymphoma, the former medical director of the University of Chicago's cancer center testified Friday during a first-of-its-kind California jury trial on whether the company should have warned consumers about its pesticides' cancer risks.
A New Jersey federal judge on Friday denied most of a biopharmaceutical company’s bid to access more than 170 emails by a cancer researcher it claims stole proprietary materials relating to an antibody, but agreed to unshield one message between the researcher and an executive of another biopharmaceutical firm.
Greenberg Traurig LLP has added a former associate general counsel for Teva Pharmaceutical Industries Ltd. to its Philadelphia office as a shareholder with a focus on pharmaceuticals and litigation, the firm recently announced.
Eleven firms will steer initial public offerings by 11 companies that are projected to raise more than $3.3 billion during the week of July 23, led by an estimated $1.5 billion offering from a Chinese e-commerce giant, potentially setting up a furious finish for the month.
A woman whose cancer-stricken mother won a $417 million jury verdict saying Johnson & Johnson's talcum baby powder caused her ovarian cancer has appealed a California judge’s “about-face” decision to vacate the award, arguing in a brief Wednesday that there was sufficient evidence to support the jury’s finding.
Endo Pharmaceuticals Inc. and Mallinckrodt LLC have launched a counterattack against a distinctive case that accuses them of fueling the opioid crisis, moving to shift any liability to drug dealers, "dark web" retailers and corrupt health care providers.
Keryx Biopharmaceuticals Inc.’s bid to escape a proposed shareholder class action claiming it inflated its stock price by hiding a drug’s supply chain problems was rejected by a Massachusetts federal judge, who however agreed to trim an allegation based on the company's statements about its financial prospects.
A California federal judge on Thursday refused to toss a $27 million verdict against Roche unit Ariosa Diagnostics Inc. for infringing Illumina Inc.'s patents for at-home prenatal testing technology, but allowed Ariosa to continue selling two versions of its tests.
The Seventh Circuit on Thursday declined to revive a man's suit against Auxilium Pharmaceuticals Inc. selected as a bellwether in multidistrict litigation over the alleged hidden risks of testosterone replacement therapy products, saying the district court properly barred his key witness from testifying.
Venture capital-backed Replimune Group Inc., represented by Morgan Lewis & Bockius LLP, on Friday picked up $101.5 million from its initial public offering as the cancer-focused biotechnology firm finished above its $15-per-share offer in its first day on the market.
Generic-drug makers Accord Healthcare Inc. and Intas Pharmaceuticals Ltd. on Thursday urged the full Federal Circuit to consider invalidating a UCB Inc. patent covering the epilepsy drug Vimpat, arguing that the court's panel relied on subjective criteria to uphold the patent instead of legally mandated objectivity.
A Texas federal judge did not let either United Healthcare or Next Health escape a suit claiming Next Health ran a $100 million kickback scheme, denying in part Next Health’s motion to dismiss United’s complaint while denying United’s motion to dismiss Next Health’s counterclaims.
GlaxoSmithKline argued Thursday that it cannot be held liable for birth defects caused after pregnant women were prescribed its postoperative nausea drug Zofran because the U.S. Food and Drug Administration has since rejected any scientific correlation between the medication and defects.
Life sciences intellectual property lawyers made big moves recently, with Wilson Sonsini snapping up an administrative patent judge for its team and Ropes & Gray and Cantor Colburn getting IP attorneys from Fitzpatrick Cella and Locke Lord. Additionally, Kirkland and O'Melveny built up their transactions practices and Baker Donelson grew its health care team.
Platform Specialty Products Corp. said Friday that it has agreed to sell its agricultural solutions business to UPL Corp. Ltd. in a $4.2 billion cash deal that saw a subsidiary of the Abu Dhabi Investment Authority and a TPG Capital-led group contribute $1.2 billion.
A Connecticut federal judge has signed off on a $54 million settlement between indirect purchasers of stroke prevention medicine Aggrenox and drugmakers Teva Pharmaceutical and Boehringer Ingelheim to end allegations the companies blocked generic alternatives to the drug from coming to the market.
The Federal Circuit on Friday ruled tribal sovereign immunity doesn’t apply in reviews at the Patent Trial and Appeal Board, rejecting an attempt from Allergan PLC to shield patents for its dry-eye medication Restasis by transferring them to a Native American tribe.
Tela Bio Inc. on Thursday urged the Third Circuit to revive its bid to force a Chubb Ltd. insurer to cover its costs to defend against a trade secrets and unfair competition lawsuit brought by competitor LifeCell Corp. over a hernia treatment product, saying a lower court applied the wrong state’s law to the dispute and ignored potentially covered defamation claims in LifeCell’s complaint.
Foundation Medicine Inc. and Guardant Health Inc. have agreed to settle litigation in Delaware federal court accusing Guardant of infringing a patent for harnessing a patient's genome to help treat cancer, along with three related challenges at the Patent Trial and Appeal Board, the companies announced Wednesday.
The Delaware Chancery Court's opinion in Cirillo Family Trust v. Moezinia is a stark reminder of both the required contents of an appraisal notice as well as the appropriate approach to take when communicating with stockholders, say attorneys with Pepper Hamilton LLP.
Hardly a day goes by where we don’t hear about another lawsuit being filed accusing pharmaceutical companies, distributors, hospitals and pharmacies of fueling the country’s addiction to opioids. But without any of these cases reaching a jury to date, it can be difficult to predict how jurors will react to these claims, says Christina Marinakis of Litigation Insights.
Less than three weeks after the U.S. Supreme Court decided Lucia v. Securities and Exchange Commission, President Donald Trump signed an executive order applying the court’s rationale in Lucia to the hiring — and firing — of all administrative law judges in the federal government, making them entirely beholden to the heads of their agencies or the president for their jobs, says Brian Casey of Barnes & Thornburg LLP.
Genetic data and techniques are becoming ever more powerful tools for explaining when and how diseases arise. They can also have very strong evidentiary value, and in some toxic tort cases, genetic findings can provide conclusive answers for a judge or jury, say Kirk Hartley and David Schwartz of ToxicoGenomica.
The use of genetic testing in tort litigation is relatively new. Such testing may uncover one or more gene variants that help identify individuals at an increased risk of developing a disease. Whole genome sequencing can be the best and most appropriate approach for toxic tort civil litigation, say Kirk Hartley and David Schwartz of ToxicoGenomica.
While Senate hearings on the nomination of Brett Kavanaugh to the U.S. Supreme Court will draw much attention during July, Congress remains very busy with fiscal year 2019 appropriations bills. The chambers may go to conference this month on the first of several appropriations "minibuses," says Layth Elhassani of Covington & Burling LLP.
People with certain personality traits tend to use certain words. A computer analysis of Judge Brett Kavanaugh’s D.C. Circuit opinions reveals that he is highly extraverted, which means that he would be a prominent voice on the U.S. Supreme Court, says Matthew Hall, a professor at the University of Notre Dame.
The recent focus on pay equity and employers’ pay practices has heightened the need to consider equal employment opportunity outcomes in performance ratings systems. Lisa Harpe and Sarah Gilbert of DCI Consulting Group discuss the current legal environment and proactive steps to examine performance ratings in the context of evaluating pay equity.
An educated guess puts the number of new litigation funders launched in the past 18 months at 30 — an astonishing number, with more to come. Is this a blessing to our legal system or something more akin to tulip mania? Maybe both, says Ralph Sutton, founder and CEO of litigation funding firm Validity Finance LLC.
Genomic data and technologies can assist both plaintiffs and defendants in toxic tort and personal injury cases in uncovering the underlying causes of disease. In coming years, the influence of genomics in civil law will be even broader than its influence in criminal law, say attorney Kirk Hartley and scientific consultant David Schwartz of ToxicoGenomica.